Good
Mostly Aligned
Patient Risk:
Low
Summary
The provided content appears consistent with the supplied label excerpts for the high-level indication and pregnancy contraindication/pregnancy-loss risk. However, no specific AI-generated prescribing claims were provided to audit in detail (only a meta-level label-summary assessment), so comprehensive evaluation of dosing, precautions, interactions, and other sections is not possible.
Category Scores
Accurate Statements
Indicated for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause.
Section 1 INDICATIONS AND USAGE
Efficacy for moderate to severe VMS due to menopause demonstrated in OASIS 1 and OASIS 2 over 12 weeks.
Section 14.1 Effects on Vasomotor Symptoms (VMS) in Postmenopausal Women
Contraindicated in pregnancy; may cause pregnancy loss or stillbirth; exclude pregnancy prior to initiation.
Section 4 CONTRAINDICATIONS; Section 5.3 Risk of Pregnancy Loss; Sections 8.1 and 8.3
Unsupported Statements
“Supported: yes / Contradicted: no / Mentioned: yes” (overall label-summary assessment without mapping to specific user claim text).
Not a specific clinical/prescribing claim; cannot be validated against the label for correctness without the underlying AI-generated patient-specific claim(s) being evaluated.
Contradictions
Important Omissions
No audit of dosage and administration (e.g., recommended 120 mg once daily at bedtime, missed dose instructions), boxed/other warnings, drug interaction dosing modifications, monitoring/lab schedule, adverse reactions, hepatic transaminase management thresholds, and administration instructions because no corresponding AI claims were provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only substantively evaluated safety-related claims (pregnancy contraindication and pregnancy loss/stillbirth risk) are aligned with the supplied label excerpts. Other safety areas were not auditable due to lack of specific AI prescribing claims.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Insufficient AI-generated claim text to comprehensively verify alignment across dosing, warnings/precautions, interactions, adverse reactions, and monitoring.
Suggested Improvement
Provide the exact AI-generated prescribing/usage statements to evaluate, then map each statement to the specific label sections (e.g., dosing, hepatic lab thresholds, CNS impairment counseling, interaction management, and administration/storage details if included).